Alprazolam is fast acting and effective for generalized anxiety disorder (GAD) and panic disorder, but its short duration of action may contribute to breakthrough symptoms between doses and make withdrawal more difficult.

Valbenazine was the first of the vesicular monoamine transporter inhibitors to be approved for the treatment of tardive dyskinesia (TD) in 2017.

Trihexyphenidyl is an anticholinergic medication that is less favored than benztropine because it must be dosed three times daily and is only available in oral formulations. 

Tetrabenazine was the original vesicular monoamine transporter inhibitor brought to market and approved for the treatment of Huntington’s disease. 

Metformin is a medication for type 2 diabetes that increases insulin sensitivity and decreases appetite. 

Deutetrabenazine was the second of the vesicular monoamine transporter inhibitors to be approved for the treatment of tardive dyskinesia (TD) in 2017.

Benztropine is an anticholinergic medication that is the go-to agent for treating and preventing antipsychotic-induced extrapyramidal symptoms (EPS).

Amantadine is a dopaminergic medication used primarily in Parkinson’s disease, but it is also helpful in drug-induced parkinsonism and has fewer anticholinergic side effects (eg, cognitive impairment, dry mouth, constipation) than other meds used to combat extrapyramidal symptoms (EPS), like benztropine.